The oncology focused biopharma firm OncoGenex Pharmaceuticals and Achieve Life Science have entered into a definitive merger agreement under which OncoGenex will acquire Achieve in an all-stock transaction. Achieve’s equity holders are expected to own 75% of the combined company’s outstanding shares and current stockholders of OncoGenex are expected to own the remaining 25% of the combined company’s outstanding shares. Following completion of the merger, OncoGenex Pharmaceut...